BIO5 members Dongkyun Kang and Clara Curiel-Lewandrowski are part of a team that hope to image nerve endings and create objective, quantitative biomarkers for chemotherapy-induced peripheral neuropathy, or CIPN, a common and painful side effect of chemotherapy drugs.

Branch Therapeutics, a University of Arizona startup co-founded by BIO5 members Christopher Hulme and Curtis Thorne, has received $4 million in seed funding to advance its development of targeted therapies for cancer and other diseases.

In 2024, the U of A ranked No. 31 globally, with 96 patents, including BIO5 director Jennifer Barton’s falloposcope for ovarian cancer and BIO5 member Steven Goldman’s heart tissue repair patch.